Evidence map›Paper›PMID 37988371›Full record

ArticlePLoS genetics2023

Phosphorylation of AHR by PLK1 promotes metastasis of LUAD via DIO2-TH signaling.

Chaohao Li, Derek B Allison, Daheng He, Fengyi Mao, Xinyi Wang, Piotr Rychahou, Ibrahim A Imam, Yifan Kong, Qiongsi Zhang, Yanquan Zhang and 9 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 1 institution in 1 country.

Chaohao LiDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0001-6486-3794
Derek B AllisonDepartment of Pathology and Laboratory Medicine, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0002-5119-2474
Daheng HeMarkey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0003-0399-2466
Fengyi MaoDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0001-7785-6606
Xinyi WangDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0002-8869-8292
Piotr RychahouMarkey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.
Ibrahim A ImamDepartment of Chemical and Materials Engineering, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0009-0001-7592-4940
Yifan KongDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Qiongsi ZhangDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Yanquan ZhangDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Jinghui LiuDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Ruixin WangDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Xiongjian RaoDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Sai WuDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
B Mark EversMarkey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.
Qing ShaoDepartment of Chemical and Materials Engineering, University of Kentucky, Lexington, Kentucky, United States of America.
Chi WangMarkey Cancer Center, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0001-8984-4995
Zhiguo LiDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.
Xiaoqi LiuDepartment of Toxicology and Cancer Biology, University of Kentucky, Lexington, Kentucky, United States of America.ORCID 0000-0002-6613-1746
University of Kentucky · US

Funding

University of Kentucky Markey Cancer Center Support Grant ECIA SupplementP30CA177558 · NCI · UNIVERSITY OF KENTUCKY · PI Jennifer F Rogers · 2013 to 2026
$38.3M
Plk1 in Chemo-resistance of CancerR01CA157429 · NCI · UNIVERSITY OF KENTUCKY · PI XIAOQI LIU · 2011 to 2026
$3.5M
Improving chemotherapy of castration-resistant prostate cancer.R01CA196634 · NCI · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · 2016 to 2025
$3.3M
Plk1 as a prognostic biomarker for prostate cancerR01CA264652 · NCI · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · 2021 to 2025
$2.7M
Enhancing the efficacy of androgen signaling inhibitors in prostate cancerR01CA256893 · NCI · UNIVERSITY OF KENTUCKY · PI LIU, XIAOQI · 2021 to 2025
$2.4M
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic EfficacyR01CA266579 · NCI · UNIVERSITY OF KENTUCKY · PI Zhiguo Li · 2022 to 2026
$2.2M
NCI NIH HHS P30 CA177558NCI NIH HHS R01 CA157429NCI NIH HHS R01 CA196634NCI NIH HHS R01 CA256893NCI NIH HHS R01 CA264652NCI NIH HHS R01 CA266579
6 · The paper itself

Abstract

Metastasis of lung adenocarcinoma (LUAD) is a major cause of death in patients. Aryl hydrocarbon receptor (AHR), an important transcription factor, is involved in the initiation and progression of lung cancer. Polo-like kinase 1 (PLK1), a serine/threonine kinase, acts as an oncogene promoting the malignancy of multiple cancer types. However, the interaction between these two factors and their significance in lung cancer remain to be determined. In this study, we demonstrate that PLK1 phosphorylates AHR at S489 in LUAD, leading to epithelial-mesenchymal transition (EMT) and metastatic events. RNA-seq analyses reveal that type 2 deiodinase (DIO2) is responsible for EMT and enhanced metastatic potential. DIO2 converts tetraiodothyronine (T4) to triiodothyronine (T3), activating thyroid hormone (TH) signaling. In vitro and in vivo experiments demonstrate that treatment with T3 or T4 promotes the metastasis of LUAD, whereas depletion of DIO2 or a deiodinase inhibitor disrupts this property. Taking together, our results identify the AHR phosphorylation by PLK1 and subsequent activation of DIO2-TH signaling as mechanisms leading to LUAD metastasis. These findings can inform possible therapeutic interventions for this event.

Indexed as

Adenocarcinoma of LungLung NeoplasmsCell ProliferationEpithelial-Mesenchymal TransitionHumansIodide PeroxidasePhosphorylationPolo-Like Kinase 1Protein Serine-Threonine KinasesReceptors, Aryl HydrocarbonThyroid HormonesIodide PeroxidasePolo-Like Kinase 1Protein Serine-Threonine KinasesReceptors, Aryl HydrocarbonThyroid Hormones

Identifiers

PMID37988371
PMCPMC10662729
OpenAlexW4388858854

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.